20/20 Biolabs Posts Record Q2 Cancer Testing Revenue, Secures Major Firefighter Screening Deals, and Launches Retail Pilot
AIDX is trading near its 52-week low of $0.401 (11% above the low) on light trading volume (0.1× avg).
Summary
20/20 Biolabs achieved its best-ever quarterly cancer testing revenue in Q2 2026, announced major firefighter screening contracts, and launched a new retail pilot with Giant Food, signaling commercial momentum despite recent financial challenges.
Key Events · Earnings and Guidance · AIDX
-
Record Q2 Cancer Testing Revenue
Preliminary unaudited results show the highest quarterly cancer testing revenue in company history, with expectations for strong year-over-year growth in Q3 and Q4 2026.
-
Major Firefighter Screening Contracts
Secured Maryland Firefighter Cancer Screening Program with 18 departments and 1,400+ participants, and selected for Vermont program covering up to 4,500 firefighters starting Q3 2026.
-
New Retail Pilot with Giant Food
Launching a 3-month pilot in August 2026 for OneTest for Longevity at Giant Food stores, offering capillary blood collection and at-home kits.
-
CEO's East Asia Trip for Expansion
CEO Jonathan Cohen completed a two-week trip to Taipei, Tokyo, and Seoul, targeting commercial expansion, real-world data acquisition, and M&A opportunities.
Analysis · AIDX · Industrial Applications And Services
Preliminary Q2 2026 results delivered the company's highest quarterly cancer testing revenue yet, accompanied by notable customer wins—including a Maryland firefighter program with over 1,400 participants and selection for a Vermont initiative covering up to 4,500 firefighters. A new pilot with Giant Food for its Longevity test and the CEO's East Asia trip to pursue commercial and M&A opportunities add strategic momentum. These updates land against a backdrop of recent financial distress and a Nasdaq delisting notice, making any positive commercial traction material for the investment thesis.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 28.8% of the 1700 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AIDX was trading at $0.44 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.4M. The 52-week trading range was $0.40 to $50.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.